About
Written By
Taesik Yoon
Supplementary Review: Avanos Medical (AVNS), May 3, 2024
Buoyed by organic growth of 9% in Digestive Health, which benefited from the persistence of strong demand for NeoMed from the continued adoption of the new [...]
Close Out: Pilgrim’s Pride (PPC), May 3, 2024
Since our last review on March 28, PPC’s stock has continued to outperform, rising about 7% even as the equity market as a whole has seen a pullback. As has been [...]
Supplementary Review: Deluxe (DLX), May 2, 2024
The Q1 results represented a good start to 2024 with both revenue and earnings comfortably exceeding their consensus estimates of $526.3 million and 71 cents [...]
Supplementary Review: Forrester Research (FORR), May 2, 2024
FORR reported a 12.0% decline in Q1 revenue from the prior year to $100.1 million. Research segment revenue was lower by 5.3% to $76.6 million due to less demand [...]
New Recommendation (April 30, 2024)
They say that the definition of insanity is doing the same thing over and over and expecting different results. If so, then that suggests the CEO of data and [...]
About
Written By